Newsletter

www.PennyStockAlerts.com does its best to bring you accurate information but errors may and sometimes do occur. Always do your own research before investing. PennyStockAlerts.com is not a licensed financial advisor.  This is a paid advertisement, not a solicitation or recommendation to buy or sell securities.

Today's "Exclusive" High Priced Marijuana Monster Play is PUGE - Puget Technologies

About Puget Technologies

Headquartered in Ft. Lauderdale, Florida, Puget Technologies acquires, develops and sells leading edge consumer oriented products ready for rapid commercialization. Puget plans to become a recognized market leader in its product categories. Much of its resources are dedicated to research and development in order to provide consumers with quality options while meeting the expectations of its investors.

PUGE is in the #1 hottest and most popular sector of the entire OTC market, Medical Marijuana!

Just TODAY PUGE announced major news that could be the catalyst to ignite a monster potential rally.

Puget Technologies revealed today its new subsidiary, Cannabis BioTech is in negotiations with a leading international medical marijuana consultant to round out its research and development team.

Through his California based research firm, this prominent international authority designs and builds effective and efficient programs to assist dispensaries and medical cannabis companies to produce superior products.

Amid changing attitudes about marijuana, Cannabis Biotech is dedicated to developing medicinal cannabinoid delivery options using the latest scientific advances. The product development being conducted by Cannabis BioTech is expected to add to the growing body of data demonstrating marijuana’s medicinal benefits.

President and CEO of Puget Technologies Ron Leyland said, “We are very close to completing negotiations which will result in adding more strength to our scientific team and accelerating the development of our line of alternate delivery options.” He added, “The 1.7 Billion dollar U.S. medical marijuana market is expected to quadruple in size during the next five years, and having such expertise onboard will ensure our frontrunner position in the industry.”

More information about Cannabis BioTech can be found at http://www.cannabisbiotech.com.

Most people probably don't realize that medical marijuana is a $1.7 billion industry.  And now with states like WA and CO passing laws to allow recreational marijuana use...there is a whole new world opening up.  While the medical marijuana industry may quadruple, we could see even MORE impressive growth from the recreational marijuana industry.

Everyone knows penny traders are gaga for hot medical marijuana plays.  That's a proven fact.

PUGE looks like it's releasing exciting press releases just as eager traders are hungry for profitable medical marijuana trades.  This could be a match made in heaven.

As traders discover PUGE, this ticker could heat up in an incredible way.

PUGE's high price tag could also attract the "big money" traders who generally shy away from low priced tickers like the ones we normally see.  The "ritzy" Wall Street types usually prefer higher share prices...and PUGE delivers there, which could add to its overall upside.

However, anything is possible and it's critical to make sure you trade with caution and protect your downside.

** Any alert I send out could cause a total loss.  In my personal opinion, no matter how much potential any company has, 99% of the time all that matters is HOW THE STOCK TRADES. If a stock doesn’t trade well, nothing else matters.  Don’t believe the hype out there, especially not the hype from me…the trading action tells the real story.  Be sure to use a tight stop, book profits when they become available, never let any one trade move too far against you, watch out for gaps, make sure the stock is trading in a healthy way before you enter, and monitor it closely to make sure momentum is positive. (Amateur biased unlicensed opinions) **

Best of all, PUGE's new subsidiary Cannabis Biotech is focused on alternate delivery technology.

Alternate delivery means taking marijuana without smoking it.  It could mean eating it, nasal spray, capsules, anything.  Alternate delivery is super popular with medical users, and is gaining in popularity because of the stigma and health problems of smoking.

PUGE has EVERY single thing it takes to get popular with traders.  Wall Street is one big popularity contest, one big fashion show...and PUGE seems to have the "in style" sector that could get traders to go bananas!

With fresh press releases out to ignite the magic spark, the time for PUGE could be right now.

Keep your eyes focused on PUGE, this one could get VERY interesting.

Don’t ever invest based on what I say.  Do your own research and consult with a licensed professional before investing, only invest what you are prepared to lose. Any statements and opinions given are amateur and biased and should be treated as such. Past performance does not indicate future performance in any way. The performance of all alerts uncompensated and compensated in no way predict the performance of current and/or upcoming alerts. Check the latest SEC filings before investing, and research other information on the risks of investing in microcap companies at www.sec.gov

Disclaimer – This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by Focus Media.  Any reference to “we” or “our” refers to Focus Media. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore unqualified to give investment recommendations. Always do your own research and consult with an licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
 
 
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on EOD or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices.
 
 

We have been compensated thirty thousand dollars cash via bank wire to conduct investor relations advertising and marketing for PUGE by a third party, Equities Awareness Group.   This compensation is a major conflict of interest in our ability to be unbiased regarding PUGE. Therefore, this communication should be viewed as a commercial advertisement only.  We have not investigated the background of the third party or parties. The third party, profiled company, or affiliates of either, has likely hired Focus Media because the party would like to liquidate a large amount of shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. At times, before we begin our advertising the hiring third party or their affiliate may receive a moderate referral fee from our compensation payment. Focus Media’s business model is to receive financial compensation to promote public companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors. 

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Focus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. See full disclaimer at www.pennystockalerts.com/disclaimer